Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 known ✓ | P08588 | 5/20 | 0.96 |
| ▸ | HTR3E known ✓ | A5X5Y0 | 3/20 | 0.96 |
| ▸ | HTR3B known ✓ | O95264 | 3/20 | 0.96 |
| ▸ | HTR3A known ✓ | P46098 | 3/20 | 0.96 |
| ▸ | HTR3D known ✓ | Q70Z44 | 3/20 | 0.96 |
| ▸ | HTR3C known ✓ | Q8WXA8 | 3/20 | 0.96 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 2/20 | 0.96 |
| ▸ | HTR1A known ✓ | P08908 | 3/20 | 0.66 |
| ▸ | HTR1B known ✓ | P28222 | 2/20 | 0.66 |
| ▸ | HTR1D known ✓ | P28221 | 1/20 | 0.66 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.57 |
| ▸ | HTR7 known ✓ | P34969 | 2/20 | 0.55 |
| ▸ | HTR2B known ✓ | P41595 | 1/20 | 0.55 |
| ▸ | HTR6 known ✓ | P50406 | 1/20 | 0.55 |
| ▸ | LTA4H | P09960 | 4/20 | 0.62 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2302729 | 1.00 | ADRB1 (0.96) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL2410870 | 0.98 | ADRB1 (1.00) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL234280 | 0.98 | ADRB1 (1.00) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| Bromide SCHEMBL11070661 | 0.96 | ADRB1 (0.96) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| Piperazine SCHEMBL8590918 | 0.96 | ADRB1 (0.96) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| Hydrochloric Acid SCHEMBL7921830 | 0.95 | ADRB1 (0.86) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL2881283 | 0.93 | ADRB1 (0.89) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL9058690 | 0.93 | ADRB1 (0.89) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL5237992 | 0.91 | ADRB1 (0.86) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL7171062 | 0.91 | ADRB1 (0.86) | ADRB1HTR3EHTR3BHTR3AHTR3D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108003118-A | A kind of posaconazole intermediate 1-（4- hydroxy phenyls）-4-（4- aminophenyls）The preparation process of-piperazine | 张家口市格瑞高新技术有限公司 | 2018-05-08 | — | — | CN | claimed |
| CN-115894325-B | Derivative containing aryl piperazine structure, composition and application thereof | 徐州医科大学 | 2025-05-27 | — | — | CN | disclosed |
| CN-117088829-A | Synthesis method of 1-isopropyl-4- (p-methoxyphenyl) piperazine or halogen acid salt thereof | 国药集团威奇达药业有限公司 | 2023-11-21 | — | — | CN | disclosed |
| CN-115433116-B | Acylated indoline derivative, composition and application thereof | 徐州医科大学 | 2023-07-14 | — | — | CN | disclosed |
| CN-115894325-A | Derivative containing aryl piperazine structure, composition and application thereof | 徐州医科大学 | 2023-04-04 | — | — | CN | disclosed |
| CN-115433116-A | Acylated indoline derivative, composition and application thereof | 徐州医科大学 | 2022-12-06 | — | — | CN | disclosed |
| EP-3424912-B1 | 2-AMINOTHIAZOLE DERIVATIVES, PREPARATION AND USE THEREOF | UNIV HUAZHONG SCIENCE TECH (CN) | 2022-09-07 | — | — | EP | disclosed |
| CN-113292515-B | Urea compound containing piperazine group and preparation method and application thereof | 沈阳药科大学 | 2022-05-20 | — | — | CN | disclosed |
| CN-107793362-B | Synthesis and application of phenyl pyridazinone derivative | 江苏恩华药业股份有限公司 | 2022-04-22 | — | — | CN | disclosed |
| CN-113292515-A | Urea compound containing piperazine group and preparation method and application thereof | 沈阳药科大学 | 2021-08-24 | — | — | CN | disclosed |
| EP-0126480-B1 | SUBSTITUTED ISOQUINOLINE DERIVATIVES, METHOD FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1988-01-20 | — | — | EP | disclosed |
| US-4707550-A | N-(substituted thienyl)-N'-(substituted piperazinyl)-ureas | ORTHO PHARMACEUTICAL CORPORATION (US) | 1987-11-17 | — | — | US | disclosed |
| EP-0244176-A2 | Thienopyrimidine-2,4-dione derivatives and intermediates thereof | ORTHO PHARMACEUTICAL CORPORATION (US) | 1987-11-04 | — | — | EP | disclosed |
| US-4670560-A | VASODILATING AGENTS, HYPOTENSIVE AGENTS AND/OR CARDIOVASCULAR AGENTS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1987-06-02 | — | — | US | disclosed |
| US-4652566-A | (2-HYDROXY-3-(4-PHENYLPIPERAZINYL)PROPOXY) BENZOFURAN DERIVATIVES; DECREASED SIDE EFFECTS | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 1987-03-24 | — | — | US | disclosed |
| CN-86106226-A | 20-and 21-amino steroids | — | 1987-03-18 | — | — | CN | disclosed |
| US-4559403-A | FOR TREATMENT OF CEREBRAL AND CARDIAC ISCHEMIAS | HOFFMANN-LA ROCHE INC. (US) | 1985-12-17 | — | — | US | disclosed |
| EP-0156331-A2 | Benzofuran derivatives, processes for preparing the same and antihypertensive agents containing the same | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 1985-10-02 | — | — | EP | disclosed |
| US-4544657-A | ANTISCHEMIC AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1985-10-01 | — | — | US | disclosed |
| EP-0126480-A1 | Substituted isoquinoline derivatives, method for their preparation, and pharmaceutical compositions containing these compounds | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1984-11-28 | — | — | EP | disclosed |